Top Stories
The new system can identify more than 100 molecular subtypes of central nervous system tumours using standard tissue sections.
CEO Bradley Paddock said the company is ready to reach more patients after recent FDA clearances for seven-day wear and 1-unit dosing.
The Future Health Index 2026 found half of clinicians said AI increased their capacity to see patients, while 70% said clear processes for monitoring AI tools were not yet in place.
The Stanford University spinout is initially developing the monitor for adrenal and cardiometabolic diseases.
The positive findings could establish a new standard of care for this untapped patient population.
Conference News
New findings add to prior data showing Hi-C sequencing detects clinically important lymphoma rearrangements missed or not targeted by conventional FISHCARLSBAD, Calif.--(BUSINESS WIRE)-- Arima Genomic...
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and i...
Program participants at MAI Lab Lagos, The Catholic University of Korea, and the University of Illinois Cancer Center are using the HOPPR® AI Foundry to advance projects spanning breast cancer detecti...
World's #1 children's hospital and #1 reporting platform share a goal to bring greater efficiency, quality, consistency and specialty-relevant insights to pediatric radiologyPITTSBURGH and MUNICH, Jun...
—One platform, two levels of sleep testing, matched to every patient——Company to present three posters reinforcing Wesper's autoscoring precision, AI-driven central apnea detection, and OSA phenotypin...
